Biotechnology - Biotechnology, Anti-virals

Filter

Current filters:

BiotechnologyAnti-virals

Popular Filters

1 to 25 of 169 results

NeuroVive in $150 million deal with OnCore BioPharma for hep B candidate NVP018

12-09-2014

Swedish mitochondrial medicine firm NeuroVive Pharmaceutical has signed an exclusive global out-licensing…

Anti-viralsBiotechnologyGlobalLicensingNeuroVive PharmaceuticalNVP018OnCore BioPharma

Gilead's monopoly in HIV therapies to be toppled by Viiv's Triumeq; report

Gilead's monopoly in HIV therapies to be toppled by Viiv's Triumeq; report

09-09-2014

The recent US Food and Drug Administration and European Commission approval of HIV specialist ViiV Healthcare’s…

Anti-viralsAtriplaBiotechnologyGilead SciencesGlobalDataHIVMarkets & MarketingStribildTriumeqUSAViiV Healthcare

US HHS contracts with Mapp Biopharmaceutical to develop Ebola drug

03-09-2014

The US Department of Health and Human Services has awarded a $25 million contract to Mapp Biopharmaceutical…

Anti-viralsBiotechnologyFinancialMapp BiopharmaceuticalResearchTropical diseasesUSAZMapp

Gilead gets favorable ruling in Roche arbitration

Gilead gets favorable ruling in Roche arbitration

17-08-2014

US biotech major Gilead Sciences said on Friday in a Security and Exchange Commission filing that an…

Anti-viralsArbitrationBiotechnologyBusiness FinanceBusiness FinanceGilead SciencesLegalPatentsPharmassetRocheSovaldiUSA

Positive draft guidance for hep C drug Sovaldi from UK’s NICE

Positive draft guidance for hep C drug Sovaldi from UK’s NICE

15-08-2014

In further draft guidance published today, UK drugs watchdog the National Institute for Health and Care…

Anti-viralsBiotechnologyGilead SciencesHepatitis CPricingRegulationRibavirinSovaldiUK

Vertex to drop hep C drug Incivek following poor sales

14-08-2014

Struggling US Biotech firm Vertex Pharmaceuticals has said it will cease marketing its hepatitis C treatment…

Anti-viralsBiotechnologyGilead SciencesHepatitis C treatmentIncivekJohnson & JohnsonMarkets & MarketingSovaldiTelaprevirUSAVertex Pharmaceuticals

Sanofi and PATH the first to bring large quantities of semisynthetic artemisinin antimalarial treatment to market

Sanofi and PATH the first to bring large quantities of semisynthetic artemisinin antimalarial treatment to market

12-08-2014

French drug major Sanofi and Seattle-based PATH have become the first to deliver large-scale batches…

Anti-viralsartemisininBiotechnologyMarkets & MarketingPATHSanofiUSA

Tekmira Pharma in focus as the world awaits Ebola treatment

Tekmira Pharma in focus as the world awaits Ebola treatment

06-08-2014

The outbreak of the deadly and highly infectious Ebola disease in Africa has already claimed many hundreds…

Anti-viralsBCX4430BioCryst PharmaceuticalsBiotechnologyEbolaMapp BiopharmaceuticalResearchRest of the WorldTekmira PharmaceuticalsTKM-EbolaUSA

Theraclone out-licenses HIV bNAbs to Gilead

Theraclone out-licenses HIV bNAbs to Gilead

01-08-2014

US privately-held drug developer Theraclone Sciences has entered into an agreement with biotech major…

Anti-viralsBiotechnologyBusiness FinanceGilead SciencesHIV/AIDSLicensingTheraclone SciencesUSA

Antiviral gel in condoms to kill HIV approved in Australia

Antiviral gel in condoms to kill HIV approved in Australia

28-07-2014

Australian biotech firm Starpharma says it has achieved a major milestone with the receipt of Conformity…

AnsellAnti-viralsAntibiotics and Infectious diseasesAustraliaBiotechnologyRegulationStarpharmaVivaGel

Gilead beats forecasts as Sovaldi sales soar

Gilead beats forecasts as Sovaldi sales soar

24-07-2014

US anti-virals specialist biotech firm Gilead Sciences has reported surging second-quarter 2014 sales…

Anti-viralsBiotechnologyBusiness FinanceBusiness FinanceChemistryFinancialFixed dose combinationGilead SciencesSovaldiTenofovir

Celgene's cancer drug Istodax could re-activate dormant HIV and allow it to be detected

Celgene's cancer drug Istodax could re-activate dormant HIV and allow it to be detected

23-07-2014

An anti-cancer drug developed by US biotech company Celgene Corp can re-activate dormant HIV which allows…

Aarhus UniversityAnti-viralsBiotechnologyCelgene Corp.DenmarkHIVHIV/AIDSIsodaxResearchromidepsin

Biotron’s BIT225 reverses HIV-induced impairment of the immune system

23-07-2014

Australian viral disease specialist Biotron presented data at the 20th International AIDS Conference,…

Anti-viralsAntiretroviral drugAustraliaBiotechnologyBiotronBIT225HIVHIV/AIDSImmune systemResearch

BioAlliance’s Sitavig debuts in USA; new patent granted

BioAlliance’s Sitavig debuts in USA; new patent granted

22-07-2014

French drug developer BioAlliance Pharma says that its US partner Innocutis Holdings has launched Sitavig…

Anti-viralsBioAlliance PharmaBiotechnologyHealth Medical PharmaHerpesInnocutis HoldingsLabial herpesMarkets & MarketingMedicineMicrobiologyPatentsSitavigUSA

Hepatitis C cured in co-infected HIV patients

Hepatitis C cured in co-infected HIV patients

21-07-2014

A multicenter team of researchers report that in a Phase III clinical trial, a combination drug therapy…

Anti-viralsAntiviralsBiotechnologyGilead SciencesHepatitis CResearchRibavirinsofosbuvirSovaldiThe Johns Hopkins University School of MedicineUSA

Sinovac to provide hepatitis A vaccine in Beijing tender to 2016

Sinovac to provide hepatitis A vaccine in Beijing tender to 2016

21-07-2014

China-based Sinovac Biotech has been selected by the Beijing Health Bureau as the sole supplier of inactivated…

Anti-viralsBiotechnologyChinaHealthcareSinovac BiotechVaccination

The price of NOT curing hepatitis C - by Robert Zirkelbach

The price of NOT curing hepatitis C - by Robert Zirkelbach

20-07-2014

Over the past few months, there has been increased focus on the price of a new cure for hepatitis C,…

Anti-viralsBiotechnologyFinancialHealthcareHepatitis CHepatitis CLiver transplantsMedicineTradeUSA

Canada approves Pendopharm’s all-oral ribavirin treatment Ibavyr for hepatitis C

Canada approves Pendopharm’s all-oral ribavirin treatment Ibavyr for hepatitis C

16-07-2014

Quebec-based Pendopharm, a division of privately-held Canadian drugmaker Pharmascience, says the regulator…

Anti-viralsBiotechnologyCanadaIbavyrPendopharmPharmascienceRegulation

US Senators press for details on Gilead’s Sovaldi pricing

US Senators press for details on Gilead’s Sovaldi pricing

12-07-2014

Adding to previous criticism from the likes of the medical humanitarian organization Medecins Sans Frontieres…

Anti-viralsBiotechnologyGilead SciencesPoliticsPricingSovaldiUSA

Australia’s TGA clears the way for Gilead’s Sovaldi for hepatitis C

Australia’s TGA clears the way for Gilead’s Sovaldi for hepatitis C

08-07-2014

Australian health care regulator the Therapeutic Goods Administration (TGA) has approved the use of US…

Anti-viralsAustraliaBiotechnologyGilead SciencesRegulationSovaldi

Gilead submits for approval of hepatitis C drug Sovaldi in Japan

Gilead submits for approval of hepatitis C drug Sovaldi in Japan

27-06-2014

US biotech firm Gilead Sciences revealed this morning it has submitted a New Drug Application to Japan's…

Anti-viralsBiotechnologyGilead SciencesJapanRegulationSovaldi

Vertex licenses novel influenza treatment VX-787 to Janssen

Vertex licenses novel influenza treatment VX-787 to Janssen

18-06-2014

US biotech firm Vertex Pharmaceuticals has inked a deal with health care giant Johnson & Johnson subsidiary…

Anti-viralsBiotechnologyGlobalHealth Medical PharmaJanssenJohnson & JohnsonLicensingVertex PharmaceuticalsVX-787

Gilead’s ledipasvir/sofosbuvir achieved 100% SVR12 among chronic hepatitis C patients in Japan

Gilead’s ledipasvir/sofosbuvir achieved 100% SVR12 among chronic hepatitis C patients in Japan

16-06-2014

US anti-virals major Gilead Sciences has released strong top-line results from a Phase III clinical trial…

Anti-viralsBiotechnologyGilead SciencesJapanledipasvirRegulationResearchsofosbuvirSovaldi

UK NICE consults on draft guidance for Gilead’s hepatitis C drug Sovaldi

UK NICE consults on draft guidance for Gilead’s hepatitis C drug Sovaldi

16-06-2014

In draft recommendations published today, UK health care watchdog the National Institute for Health and…

Anti-viralsBiotechnologyGilead SciencesPricingRegulationSovaldiUK

1 to 25 of 169 results

Back to top